Astellas Pharma (OTCMKTS:ALPMY) Posts Earnings Results, Beats Expectations By $0.12 EPS

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) announced its earnings results on Friday. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.15 by $0.12, Zacks reports. The business had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.02 billion. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%.

Astellas Pharma Stock Up 0.2 %

Shares of Astellas Pharma stock traded up $0.02 during trading on Tuesday, reaching $10.08. The company had a trading volume of 77,003 shares, compared to its average volume of 223,883. The company has a market cap of $18.24 billion, a price-to-earnings ratio of -45.82 and a beta of 0.31. The firm's fifty day moving average is $9.61 and its 200-day moving average is $10.03. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.80 and a current ratio of 1.04. Astellas Pharma has a fifty-two week low of $8.37 and a fifty-two week high of $13.14.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.